Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Enzo Biochem Presents New AmpiProbe Nucleic Acid Amplification Platform Details

RELATED NEWS
Trade ENZ now with 

Enzo Biochem Inc. (ENZ: Quote) announced that it has made its first peer-reviewed presentation of its novel AmpiProbe platform, encompassing low cost, and high sensitivity, real time nucleic acid amplification and detection assays, at the annual meeting in London of the European Society of Clinical Microbiology and Infectious Diseases or ESCMID.

The company said its presentation, titled "Quantitative Detection of HCV RNA in Human Plasma-Serum using the Enzo AmpiProbe HCV RNA Assay," detailed the specifications and performance characteristics of the first diagnostic product developed utilizing the AmpiProbe platform.

Enzo's AmpiProbe Hepatitis C virus RNA assay was tested over hundreds of clinical samples and found to be reproducible, accurate and precise, the presentation indicated. In addition, the AmpiProbe HCV RNA assay was found, as compared to similar diagnostics products, to achieve a greater enhanced sensitivity that allows for a more convenient and efficient workflow requiring significantly less starting material.

Click here to receive FREE breaking news email alerts for Enzo Biochem and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Fashion retailer Gap Inc. said Thursday after the markets closed that its second quarter profit rose 10% from last year, helped by higher sales and a gain from asset sale. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarter sales. Separately, Gap announced plans to enter India through franchise-operated Gap brand stores in 2015. While buying interest was somewhat subdued, stocks moved mostly higher over the course of the trading day on Thursday. The gains on the day extended the recent upward trend by the markets, lifting the S&P 500 to a new record closing high. Republicans have not found much to like about President Barack Obama's nearly six years in office, but the results of a new Washington Post-ABC News poll show that a vast majority support the president's decision to launch airstrikes in Iraq.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.